Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed advanced and/or metastatic solid tumors refractory to
standard curative or palliative therapy and for which no other conventional therapy
exists

- Measurable or evaluable metastatic disease

- No brain metastases unless previously treated and no evidence of recurrence

- No lymphoma or other hematologic malignancy

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0-1

Life expectancy:

- At least 3 months

Hematopoietic:

- Granulocyte count at least 2,000/mm^3

- Platelet count at least 100,000/mm^3

- Hematocrit at least 30% (transfusion allowed)

- No known bleeding disorder

Hepatic:

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- ALT and AST no greater than 1.5 times ULN (3 times ULN if liver metastases present)

- Alkaline phosphatase no greater than 1.5 times ULN (3 times ULN if liver metastases
present)

- PT and PTT no greater than 1.5 times ULN

- Hepatitis B surface antigen negative

- No chronic active hepatitis B

- No end-stage liver disease

Renal:

- Creatinine no greater than 2.0 mg/dL

- No urinary tract stones

- No end-stage renal disease

Cardiovascular:

- No known valvular disease

- No known clinically significant atherosclerotic disease, peripheral vascular disease,
or arterial aneurysm

- No unstable angina

- No artificial heart valves

Pulmonary:

- No severe oxygen-dependent chronic obstructive pulmonary disease

Other:

- No artificial implant that cannot be removed (e.g., prosthetic hips or knees or other
devices)

- No permanent central venous catheters

- No gallstones

- No active infection

- No documented Salmonella infection

- No tumor fever or fever of unknown origin or cause

- Daily maximum temperature no greater than 38.0 degrees Celsius

- HIV negative

- No documented immunodeficiency

- No other life-threatening illness

- No history of allergic reaction or hypersensitivity to quinolone or cephalosporin
antibiotics

- No commercial food handlers, day-care workers, or health-care workers

- No patients unable to avoid close personal contact with severely immunosuppressed
individuals (e.g., other patients on myelosuppressive cancer chemotherapy)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- At least 4 weeks since prior biologic therapy and recovered

Chemotherapy:

- At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or
nitrosoureas) and recovered

Endocrine therapy:

- At least 2 weeks since prior hormonal therapy and recovered

- No concurrent steroids that could depress the immune system unless indicated for
severe reactions

Radiotherapy:

- At least 4 weeks since prior radiotherapy and recovered

Surgery:

- At least 2 weeks since prior surgery and recovered

- No prior splenectomy

- No concurrent palliative surgery

Other:

- Recovered from any other prior anticancer therapies

- No concurrent antibiotics

- No concurrent immunosuppressives or any other medications that could suppress the
immune system

- No other concurrent treatment for malignancy

- No requirement for immediate palliative treatment